{
  "schemaVersion": "2.0",
  "lastUpdated": "2025-01-09",
  
  "substance": {
    "id": "lsd_001",
    "name": "Lysergic Acid Diethylamide (LSD)",
    "aliases": ["Acid", "Blotter", "Tabs", "Doses"],
    "synthesisHistory": {
      "year": 1938,
      "chemist": "Albert Hofmann",
      "location": "Switzerland",
      "origin": "Entirely synthetic, man-made"
    },
    "classification": {
      "primary": "classical_serotonergic_psychedelic",
      "secondary": ["ergoline", "phenethylamine", "tryptamine"],
      "mechanism": "5-HT2A_agonist",
      "receptorAffinity": {
        "5HT2A": "high",
        "5HT1A": "moderate",
        "5HT2C": "moderate"
      },
      "chemicalStructure": "Contains both phenethylamine and tryptamine groups",
      "derivedFrom": "Lysergic acid"
    },
    "legalStatus": {
      "US": "Schedule I",
      "international": "Controlled in most jurisdictions",
      "consequences": "Criminalization creates barriers to research and safe use"
    },
    "prevalenceData": {
      "recreationalUseIncrease": {
        "period": "early 2000s to late 2010s",
        "increase": "200%",
        "citation": "baxter_2024"
      },
      "firstTimeUserDemographics": {
        "averageAge": 21,
        "genderDistribution": "predominantly male",
        "priorKnowledge": "most well-informed before use",
        "harmReductionPractices": "commonly use familiar settings with close friends",
        "citation": "baxter_2024"
      },
      "emergencyRoomVisits": {
        "rate": 1,
        "unit": "percent",
        "year": 2020,
        "context": "Of all LSD users seeking emergency care",
        "citation": "canady_2023"
      },
      "poisonControlCases": {
        "ageGroup": "13-19",
        "prevalence": "majority of cases",
        "context": "Combined LSD and psilocybin data",
        "citation": "malcolm_2022"
      }
    },
    "dosing": {
      "microdose": {
        "range": {"min": 5, "max": 20, "unit": "mcg"},
        "description": "Sub-perceptual doses",
        "ratio": "1/10th to 1/20th of normal dose",
        "commonSchedule": "1 day on, 2 days off",
        "citations": ["hutten_2019", "family_2020"]
      },
      "minidose": {
        "range": {"min": 21, "max": 30, "unit": "mcg"},
        "description": "Between micro and threshold, some perceptual effects",
        "citation": "holze_2021"
      },
      "threshold": {"value": 25, "unit": "mcg"},
      "light": {"min": 25, "max": 75, "unit": "mcg"},
      "common": {"min": 75, "max": 150, "unit": "mcg"},
      "strong": {"min": 150, "max": 300, "unit": "mcg"},
      "heavy": {"min": 300, "unit": "mcg"},
      "therapeutic": {
        "typical": {"min": 75, "max": 150, "unit": "mcg"},
        "range": {"min": 50, "max": 200, "unit": "mcg"},
        "perKg": {"min": 0.5, "max": 2, "unit": "mcg/kg"},
        "clinicalStudyDoses": [25, 50, 100, 200],
        "citation": "fuentes_2020"
      },
      "recreational": {
        "typical": {"min": 50, "max": 150, "unit": "mcg"},
        "range": {"min": 10, "max": 400, "unit": "mcg"},
        "citation": "leonard_2018"
      },
      "egoDissolution": {
        "threshold": 200,
        "unit": "mcg",
        "description": "Doses at or above this considered high/capable of inducing ego-dissolution",
        "citation": "engel_2024a"
      },
      "overwhelmingDoses": {
        "threshold": 500,
        "unit": "mcg",
        "description": "Extremely high doses producing overwhelming effects",
        "risks": "dangerous psychological outcomes",
        "citation": "bremler_2023"
      },
      "weightDependence": true,
      "toleranceFactor": true,
      "individualVariability": ["tolerance", "weight", "age"],
      "doseResponseRelationship": {
        "description": "Effects increase with dose; positive effects plateau around 100 mcg while anxiety risk increases at higher doses",
        "positiveEffectsPlateau": 100,
        "anxietyIncrease": "Higher doses",
        "citation": "holze_2021"
      }
    },
    "pharmacokinetics": {
      "absorption": {
        "route": "oral_primary",
        "alternativeRoutes": ["intravenous", "ocular"],
        "bioavailability": "high_oral"
      },
      "onset": {
        "phase": "onset",
        "duration": {"min": 30, "max": 60, "unit": "minutes"},
        "citation": "petersen_2020"
      },
      "peak": {
        "phase": "peak",
        "duration": {"min": 120, "max": 180, "unit": "minutes"},
        "citation": "petersen_2020"
      },
      "totalDuration": {
        "typical": {"min": 8, "max": 12, "unit": "hours"},
        "phases": [
          {
            "phase": "onset",
            "duration": {"min": 30, "max": 60, "unit": "minutes"}
          },
          {
            "phase": "peak",
            "duration": {"min": 120, "max": 180, "unit": "minutes"}
          },
          {
            "phase": "subsiding",
            "duration": {"min": 120, "max": 180, "unit": "minutes"}
          },
          {
            "phase": "return_to_baseline",
            "duration": "variable"
          }
        ],
        "citation": "petersen_2020"
      },
      "metabolism": "hepatic",
      "elimination": "renal"
    },
    "subjectiveEffects": {
      "perceptual": [
        "visual_hallucinations",
        "altered_time_perception",
        "distorted_sensory_experiences",
        "enhanced_colors",
        "geometric_patterns",
        "trails",
        "visual_snow"
      ],
      "cognitive": [
        "altered_identity_perception",
        "depersonalization",
        "derealization",
        "enhanced_introspection",
        "novel_thought_patterns"
      ],
      "emotional": [
        "euphoria",
        "heightened_emotions",
        "emotional_lability",
        "anxiety_possible",
        "fear_possible"
      ],
      "somatic": [
        "increased_body_temperature",
        "increased_heart_rate",
        "increased_blood_pressure",
        "pupil_dilation",
        "nausea_possible"
      ],
      "intensity": "Can be more intense than other illicit substances",
      "overwhelming": "May overwhelm unprepared users",
      "variability": "Highly individualized, influenced by set and setting",
      "citations": ["baxter_2024", "fuentes_2020", "johnson_2019"]
    },
    "toleranceDevelopment": {
      "rate": "rapid",
      "mechanism": "Receptor downregulation",
      "crossTolerance": ["psilocybin", "mescaline", "other_5HT2A_agonists"],
      "duration": "Repeated use necessitates higher doses",
      "resetTime": "3-7 days typically required",
      "citation": "fuentes_2020"
    },
    "addictionPotential": {
      "physical": "none",
      "psychological": "minimal",
      "dependence": "Does not typically cause physical dependence",
      "withdrawal": "No withdrawal symptoms",
      "compulsiveUse": "rare",
      "citations": ["martins_2023", "fuentes_2020"]
    },
    "toxicityProfile": {
      "physiological": "low",
      "overdoseRisk": "low_compared_to_other_drugs",
      "lethalDose": "very_high",
      "safetyRatio": "high_therapeutic_index",
      "rarityCases": {
        "description": "Rare case reports of overdose",
        "effects": ["coma", "hyperthermia", "bleeding"],
        "deaths": "Accidental deaths documented but rare",
        "citations": ["leonard_2018", "martins_2023"]
      },
      "citation": "baxter_2024"
    },
    "therapeuticPotential": {
      "underInvestigation": true,
      "targetConditions": [
        "depression",
        "anxiety",
        "PTSD",
        "addiction",
        "end_of_life_distress"
      ],
      "citations": ["baxter_2024", "fuentes_2020", "anderson_2019"]
    }
  },

  "routesOfAdministration": [
    {
      "id": "roa_oral_lsd_001",
      "route": "oral",
      "substanceId": "lsd_001",
      "commonality": "most_common",
      "preparations": [
        {
          "type": "blotter_paper",
          "description": "Small squares of paper impregnated with LSD",
          "commonality": "most_common",
          "risks": [
            "Dosage uncertainty due to uneven distribution",
            "Hot spots with higher concentrations",
            "Cold spots with little to no LSD",
            "Difficult to achieve consistent microdosing"
          ],
          "citations": ["abraham_1993", "miller_2024"]
        },
        {
          "type": "liquid",
          "description": "LSD dissolved in water or alcohol",
          "advantages": ["More consistent dosing possible", "Volumetric measurement"],
          "citation": "abraham_1993"
        },
        {
          "type": "sugar_cubes",
          "description": "Sugar cubes with LSD applied",
          "citation": "abraham_1993"
        },
        {
          "type": "gelatin",
          "description": "Gelatin squares or 'window panes'",
          "advantages": ["More stable than paper"]
        }
      ],
      "onset": {"min": 30, "max": 60, "unit": "minutes"},
      "advantages": [
        "Relatively safe in controlled settings",
        "Familiar route",
        "Slower onset allows adjustment"
      ],
      "risks": [
        "Dosage uncertainty with illicit sources",
        "Users may redose before first dose takes effect",
        "Unpredictable effects if dose unknown"
      ],
      "safetyConsiderations": [
        "Test substances",
        "Start with known low dose",
        "Wait adequate time before considering redosing",
        "Use volumetric dosing for consistency"
      ]
    },
    {
      "id": "roa_iv_lsd_001",
      "route": "intravenous",
      "substanceId": "lsd_001",
      "commonality": "rare",
      "context": "Clinical research primarily",
      "onset": "very_rapid",
      "risks": [
        "Faster onset leads to more intense experience",
        "More difficult to control dose",
        "Overwhelming effects possible",
        "Increased risk of adverse reactions",
        "Overdose risk higher"
      ],
      "requirements": [
        "Medical supervision essential",
        "Clinical or research setting only",
        "Not recommended outside controlled environments"
      ],
      "citation": "garcia-romeu_2018"
    },
    {
      "id": "roa_ocular_lsd_001",
      "route": "ocular",
      "substanceId": "lsd_001",
      "commonality": "very_rare",
      "evidenceBase": "limited",
      "risks": [
        "Unpredictable dosage",
        "Faster onset than oral",
        "Lack of safety data"
      ],
      "recommendation": "Not recommended outside controlled research",
      "citation": "Literature mentions but limited data"
    }
  ],

  "lsdSpecificRiskFactors": [
    {
      "id": "rf_lsd_dosage_001",
      "name": "High Dose Effects",
      "category": "dosage",
      "severity": "high",
      "doseThresholds": [
        {
          "dose": 50,
          "unit": "mcg",
          "badDrugEffects": 9,
          "percentUnit": "percent",
          "citation": "holze_2022"
        },
        {
          "dose": 100,
          "unit": "mcg",
          "badDrugEffects": 27,
          "percentUnit": "percent",
          "citation": "holze_2022"
        },
        {
          "dose": 200,
          "unit": "mcg",
          "badDrugEffects": 31,
          "percentUnit": "percent",
          "egoDissolution": "capable",
          "citations": ["holze_2022", "engel_2024a"]
        },
        {
          "dose": 500,
          "unit": "mcg",
          "description": "Extremely high, overwhelming effects",
          "risks": "dangerous psychological outcomes",
          "citation": "bremler_2023"
        }
      ],
      "physiologicalEffects": {
        "heartRate": {
          "finding": "Peak heart rate >100 bpm in 25% at 200 mcg",
          "citation": "holze_2022"
        },
        "bodyTemperature": {
          "finding": "Peak temperature >38°C in 34% at 200 mcg",
          "citation": "holze_2022"
        }
      },
      "specificRisks": [
        "psychological_distress",
        "physiological_discomfort",
        "anxiety",
        "panic",
        "ego_dissolution",
        "confusion"
      ],
      "doseResponseRelationship": "Clear increase in adverse effects with dose"
    },
    {
      "id": "rf_lsd_psychiatric_history_001",
      "name": "Prior Mental Health Conditions",
      "category": "psychiatric",
      "severity": "high",
      "specificConditions": [
        {
          "condition": "psychosis_history",
          "personalHistory": "high_risk",
          "familyHistory": "elevated_risk",
          "risks": [
            "Trigger psychotic episodes",
            "Exacerbate symptoms",
            "Prolonged psychotic reactions"
          ],
          "citations": ["kopra_2022", "white_2024"]
        },
        {
          "condition": "bipolar_disorder",
          "personalHistory": "high_risk",
          "familyHistory": "elevated_risk",
          "risks": [
            "Manic episode induction",
            "Mood destabilization"
          ],
          "citations": ["honk_2024", "marrocu_nd"]
        },
        {
          "condition": "personality_disorders",
          "negativeResponseRate": 31,
          "unit": "percent",
          "relativeTo": "general_population",
          "adverseResponseRisk": "4-fold elevation",
          "longTermNegativeResponse": "associated",
          "citations": ["marrocu_nd", "bremler_2023"]
        },
        {
          "condition": "anxiety_disorders",
          "risk": "worsening_symptoms",
          "prevalence": "87% worsening in those with negative responses",
          "citation": "bremler_2023"
        },
        {
          "condition": "depression",
          "risk": "potential_worsening",
          "context": "Especially with history",
          "citation": "bremler_2023"
        }
      ],
      "postExperiencePsychiatricDiagnosis": {
        "rate": 37.5,
        "unit": "percent",
        "context": "Developed psychiatric diagnosis after negative psychedelic experience",
        "citation": "bremler_2023"
      },
      "screening": "Essential - careful screening required"
    },
    {
      "id": "rf_lsd_inexperience_001",
      "name": "Lack of Experience with Psychedelics",
      "category": "experiential",
      "severity": "moderate_to_high",
      "description": "First-time users particularly vulnerable",
      "specificRisks": [
        "Unfamiliarity with dosing",
        "Unpredictability of effects",
        "Overwhelming experiences",
        "Inability to manage intense states"
      ],
      "firstTimeUserData": {
        "fearExperience": {
          "rate": 64.1,
          "unit": "percent",
          "severity": "generally mild",
          "impact": "Did not discourage further use",
          "citation": "baxter_2024"
        },
        "seriousAdverseEvents": {
          "rate": 0.5,
          "unit": "percent",
          "context": "Seeking emergency medical treatment",
          "citation": "baxter_2024"
        }
      },
      "harmReduction": [
        "Comprehensive education",
        "Start with low doses",
        "Experienced trip sitter present",
        "Safe, familiar setting",
        "Adequate preparation"
      ],
      "citation": "baxter_2024"
    },
    {
      "id": "rf_lsd_age_youth_001",
      "name": "Young Age (<25 years)",
      "category": "demographic",
      "severity": "moderate_to_high",
      "ageRange": {"min": 13, "max": 25},
      "specificRisks": [
        "Developing brain vulnerability",
        "Higher emergency treatment rates",
        "Lower risk awareness",
        "Impulsivity",
        "Emotional regulation difficulties"
      ],
      "prevalenceData": {
        "negativeEffectsUnder25": {
          "rate": 53,
          "unit": "percent",
          "context": "Of those with negative effects",
          "citation": "bremler_2023"
        },
        "poisonControlCases": {
          "ageRange": "13-19",
          "prevalence": "majority",
          "substances": "LSD and psilocybin combined",
          "citation": "malcolm_2022"
        },
        "emergencyTreatment": {
          "trend": "Higher rates in younger users",
          "citation": "marazziti_2024"
        }
      },
      "mechanisms": [
        "Neurotransmitter system susceptibility",
        "Ongoing brain development",
        "Psychological impact of intense experiences in developing brain"
      ],
      "citations": ["bremler_2023", "malcolm_2022", "marazziti_2024", "breeksema_2022"]
    },
    {
      "id": "rf_lsd_prior_negative_001",
      "name": "Prior Negative Psychedelic Experiences",
      "category": "experiential",
      "severity": "moderate",
      "description": "History of challenging experiences increases future risk",
      "mechanism": "Psychological vulnerability or sensitization",
      "specificRisks": [
        "Increased likelihood of similar challenges",
        "Anticipatory anxiety",
        "Potential for re-traumatization"
      ],
      "recommendations": [
        "Exercise caution",
        "Seek professional guidance",
        "Consider whether further use appropriate",
        "Enhanced preparation if continuing"
      ],
      "citations": ["aday_2021", "evans_2023", "palmer_2022"]
    },
    {
      "id": "rf_lsd_stressful_life_001",
      "name": "Stressful Life Events or Circumstances",
      "category": "situational",
      "severity": "moderate",
      "description": "Major life changes or ongoing stress increase risk",
      "specificRisks": [
        "Anxiety during trip",
        "Panic reactions",
        "Longer-term psychological distress",
        "Difficulty managing intense emotions"
      ],
      "examples": [
        "Recent bereavement",
        "Relationship breakdown",
        "Job loss",
        "Financial stress",
        "Major life transitions"
      ],
      "recommendation": "Consider postponing use until life circumstances stabilize",
      "citation": "bremler_2023"
    },
    {
      "id": "rf_lsd_cardiovascular_001",
      "name": "Cardiovascular Conditions",
      "category": "physiological",
      "severity": "moderate_to_high",
      "description": "Pre-existing heart conditions pose elevated risk",
      "mechanism": [
        "LSD increases blood pressure",
        "Increases heart rate",
        "Increases body temperature"
      ],
      "specificConditions": [
        "Hypertension",
        "Arrhythmias",
        "Coronary artery disease",
        "Heart failure",
        "Recent myocardial infarction"
      ],
      "contraindicationType": "relative_to_absolute",
      "exclusionFromTrials": "common",
      "monitoring": [
        "Vital signs monitoring",
        "Medical supervision",
        "ECG if indicated"
      ],
      "citations": ["fuentes_2020", "holze_2021", "ghaznavi_2025", "bender_2022"]
    }
  ],

  "lsdDrugInteractions": [
    {
      "id": "interact_lsd_lithium_001",
      "substanceId": "lsd_001",
      "interactingDrug": "lithium",
      "severity": "critical",
      "contraindicationType": "absolute",
      "specificRisks": [
        "Higher risk of harm",
        "Severe adverse reactions",
        "Seizures possible",
        "Confusion",
        "Delirium"
      ],
      "mechanism": "Unknown but well-documented dangerous interaction",
      "recommendation": "Absolute avoidance",
      "citation": "ghaznavi_2025"
    },
    {
      "id": "interact_lsd_ssri_001",
      "substanceId": "lsd_001",
      "interactingDrug": "SSRIs",
      "severity": "high",
      "specificRisks": [
        "Serotonin syndrome risk",
        "Unpredictable effects",
        "May blunt psychedelic effects",
        "Potential for dangerous serotonin accumulation"
      ],
      "symptoms": [
        "Tachycardia",
        "Hypertension",
        "Hyperthermia",
        "Seizures",
        "Potentially fatal in severe cases"
      ],
      "recommendation": "Avoid combination; taper SSRIs under medical supervision if psychedelic use planned",
      "citations": ["sakai_2024", "gomez-escolar_2024", "malcolm_2022"]
    },
    {
      "id": "interact_lsd_maoi_001",
      "substanceId": "lsd_001",
      "interactingDrug": "MAOIs",
      "severity": "critical",
      "contraindicationType": "absolute",
      "specificRisks": [
        "Severe serotonin syndrome",
        "Potentially fatal interaction",
        "Unpredictable potentiation of effects"
      ],
      "recommendation": "Absolute contraindication",
      "citations": ["breeksema_2022", "ghaznavi_2025"]
    },
    {
      "id": "interact_lsd_alcohol_001",
      "substanceId": "lsd_001",
      "interactingDrug": "alcohol",
      "severity": "moderate",
      "polydrug": true,
      "specificRisks": [
        "Increased adverse effects",
        "Impaired judgment",
        "Unpredictable interactions",
        "Increased nausea"
      ],
      "recommendation": "Avoid combination",
      "citation": "kopra_2025"
    },
    {
      "id": "interact_lsd_cannabis_001",
      "substanceId": "lsd_001",
      "interactingDrug": "cannabis",
      "severity": "moderate",
      "polydrug": true,
      "commonality": "Common combination",
      "effects": "Variable - may reduce or exacerbate difficulty",
      "specificRisks": [
        "Increased anxiety in some",
        "Intensification of effects",
        "Unpredictable interactions"
      ],
      "recommendation": "Exercise caution; effects vary individually",
      "citation": "carbonaro_2016"
    }
  ],

  "lsdContraindications": [
    {
      "id": "contra_lsd_absolute_001",
      "type": "absolute",
      "conditions": [
        {
          "condition": "active_psychosis",
          "rationale": "LSD can worsen symptoms, trigger hallucinations/delusions",
          "severity": "critical",
          "citation": "fuentes_2020"
        },
        {
          "condition": "severe_organic_disease",
          "subtypes": [
            "organic_toxic_cerebral_disorder",
            "severe_neurological_disease"
          ],
          "rationale": "Physiological effects pose significant risk",
          "citations": ["bodnar_2019", "fuentes_2020"]
        },
        {
          "condition": "severe_cardiovascular_disease",
          "subtypes": [
            "uncontrolled_hypertension",
            "severe_arrhythmias",
            "recent_MI",
            "severe_heart_failure"
          ],
          "rationale": "LSD increases BP and HR; may trigger cardiovascular events",
          "citations": ["fuentes_2020", "holze_2021"]
        },
        {
          "condition": "pregnancy",
          "rationale": "Lack of safety research; potential fetal effects unknown",
          "severity": "critical",
          "citation": "fuentes_2020"
        },
        {
          "condition": "epilepsy",
          "rationale": "May increase seizure risk due to stimulating effects",
          "note": "Often excluded from clinical trials",
          "citations": ["fuentes_2020", "simonsson_2022"]
        },
        {
          "condition": "current_suicidality",
          "rationale": "Intense psychological effects may exacerbate feelings of hopelessness or despair",
          "severity": "critical",
          "citation": "holze_2022"
        }
      ]
    },
    {
      "id": "contra_lsd_relative_001",
      "type": "relative",
      "conditions": [
        {
          "condition": "mental_health_history",
          "subtypes": [
            "personality_disorders",
            "depression",
            "anxiety_disorders",
            "PTSD"
          ],
          "rationale": "Heightened risk of negative experience; requires careful screening and support",
          "requiredPrecautions": [
            "Thorough screening",
            "Comprehensive preparation",
            "Enhanced therapeutic support",
            "Close monitoring",
            "Extended integration"
          ],
          "citations": ["marrocu_nd", "sabe_2024", "bremler_2023"]
        },
        {
          "condition": "family_history_psychosis",
          "rationale": "Increased vulnerability to psychotic reactions",
          "requiredPrecautions": [
            "Extra caution",
            "Detailed family history",
            "Lower doses",
            "Enhanced monitoring"
          ],
          "citations": ["honk_2024", "henningfield_2023"]
        },
        {
          "condition": "family_history_bipolar",
          "rationale": "May trigger manic episodes in vulnerable individuals",
          "note": "Some evidence suggests safety in controlled settings for Bipolar II",
          "citations": ["honk_2024"]
        },
        {
          "condition": "trauma_history",
          "rationale": "Risk of trauma reactivation; may be therapeutic with proper support",
          "requiredPrecautions": [
            "Trauma-informed approach",
            "Specialized therapeutic support",
            "Preparation work",
            "Safety planning",
            "Grounding techniques training"
          ],
          "citations": ["bremler_2023", "gorman_2021", "weiss_2023"]
        },
        {
          "condition": "paranoid_personality_traits",
          "rationale": "LSD may amplify suspicion, distrust, anxiety, leading to paranoia",
          "citation": "fuentes_2000"
        },
        {
          "condition": "controlled_cardiovascular_conditions",
          "rationale": "Moderate BP/HR increases may be problematic; requires monitoring",
          "requiredPrecautions": [
            "Medical clearance",
            "Vital signs monitoring",
            "Medical supervision available"
          ]
        }
      ]
    }
  ],

  "lsdAdverseEvents": [
    {
      "id": "ae_lsd_anxiety_001",
      "name": "Acute Anxiety and Panic",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "mild_to_severe",
      "prevalence": [
        {
          "context": "First-time users experiencing fear",
          "rate": 64.1,
          "unit": "percent",
          "severity": "Generally mild",
          "impact": "Did not discourage further use",
          "citation": "baxter_2024"
        },
        {
          "context": "Emergency medical treatment seekers - anxiety/panic",
          "rate": 69.6,
          "unit": "percent",
          "coOccurrence": "64.1% also had confusion",
          "citation": "kopra_2022"
        },
        {
          "context": "Most frequently reported adverse effect",
          "citations": ["andersen_2021", "family_2022", "rossi_2022"]
        }
      ],
      "description": "Anxiety and panic reactions during LSD experience",
      "manifestations": [
        "Intense fear",
        "Racing heart",
        "Sense of impending doom",
        "Inability to calm down",
        "Overwhelming worry",
        "Panic attacks"
      ],
      "riskFactors": [
        "Unprepared for intensity",
        "High doses",
        "Unfamiliar setting",
        "Pre-existing anxiety",
        "Stressful life circumstances",
        "Lack of support"
      ],
      "management": [
        "Reassurance",
        "Breathing exercises",
        "Grounding techniques",
        "Environmental adjustment",
        "Benzodiazepines if severe"
      ],
      "prognosis": "Usually resolves with session; can escalate without proper support",
      "citations": ["baxter_2024", "kopra_2022", "rossi_2022"]
    },
    {
      "id": "ae_lsd_psychotic_symptoms_001",
      "name": "Acute Psychotic Symptoms",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "moderate_to_severe",
      "prevalence": {
        "persistent": 1.3,
        "unit": "percent",
        "context": "Persistent psychotic symptoms",
        "citation": "carhart-harris_2010"
      },
      "symptoms": [
        "Paranoia",
        "Hallucinations beyond typical psychedelic effects",
        "Delusions",
        "Derealization",
        "Disorganized thinking",
        "Loss of reality testing"
      ],
      "overlap": "May overlap with 'bad trip'",
      "riskFactors": [
        "Personal history of psychosis",
        "Family history of psychosis",
        "High doses",
        "Vulnerable individuals",
        "Poor set and setting"
      ],
      "duration": "Usually acute but can become prolonged",
      "management": [
        "Supportive care",
        "Benzodiazepines",
        "Antipsychotics if severe and unresponsive",
        "Medical evaluation"
      ],
      "citation": "carhart-harris_2010"
    },
    {
      "id": "ae_lsd_cognitive_impairment_001",
      "name": "Acute Cognitive Impairment",
      "category": "cognitive",
      "timeframe": "acute",
      "severity": "moderate",
      "affectedDomains": [
        "Attention",
        "Memory",
        "Executive function",
        "Concentration",
        "Problem-solving"
      ],
      "description": "Impaired cognitive functioning during experience",
      "manifestations": [
        "Difficulty focusing",
        "Short-term memory problems",
        "Inability to complete tasks",
        "Confusion",
        "Disorientation"
      ],
      "functionalImpact": "Makes experience disorienting and potentially overwhelming",
      "duration": "Resolves as drug effects subside",
      "citation": "barber_2023"
    },
    {
      "id": "ae_lsd_ego_dissolution_001",
      "name": "Ego Dissolution",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "variable",
      "doseRelationship": "More common at higher doses (200+ mcg)",
      "description": "Loss of sense of self or identity",
      "valence": "Can be positive or distressing",
      "positiveExperience": [
        "Mystical experience",
        "Unity consciousness",
        "Transcendent insights",
        "Transformative"
      ],
      "negativeExperience": [
        "Terror",
        "Confusion",
        "Panic",
        "Fear of death or insanity",
        "Loss of control"
      ],
      "individualVariability": "Highly dependent on preparation, set, setting, and support",
      "citation": "holze_2021"
    },
    {
      "id": "ae_lsd_trauma_reactivation_001",
      "name": "Trauma Reactivation",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "moderate_to_severe",
      "description": "Triggering recall of past traumatic experiences",
      "manifestations": [
        "Flashbacks to traumatic events",
        "Re-experiencing trauma",
        "Intense emotional distress",
        "Dissociation",
        "Panic"
      ],
      "examples": [
        "Sexual assault memories",
        "Combat experiences",
        "Childhood abuse",
        "Accidents",
        "Loss"
      ],
      "riskFactors": [
        "History of trauma",
        "Unprocessed trauma",
        "PTSD",
        "Lack of trauma-informed support"
      ],
      "dualNature": "Can be destabilizing or therapeutically valuable with proper support",
      "management": [
        "Trauma-informed facilitators",
        "Grounding techniques",
        "Safety planning",
        "Integration support"
      ],
      "citation": "scala_2024"
    },
    {
      "id": "ae_lsd_suicidality_acute_001",
      "name": "Suicidal Ideation and Self-Harm",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "critical",
      "prevalence": {
        "thoughtsOrActs": 20.6,
        "unit": "percent",
        "context": "Emergency medical treatment seekers",
        "citation": "kopra_2022"
      },
      "description": "Thoughts or acts of self-harm during experience",
      "riskFactors": [
        "Pre-existing mental health issues",
        "History of suicidal ideation",
        "Depression",
        "Challenging experience",
        "Overwhelming negative emotions",
        "Loss of hope"
      ],
      "causality": "Direct link unclear; may reflect underlying issues",
      "management": [
        "Immediate support",
        "Continuous monitoring",
        "Safety measures",
        "Emergency services if needed",
        "Psychiatric evaluation"
      ],
      "prevention": [
        "Thorough screening",
        "Exclude active suicidality",
        "Close monitoring during session"
      ],
      "citation": "kopra_2022"
    },
    {
      "id": "ae_lsd_cardiovascular_001",
      "name": "Cardiovascular Effects",
      "category": "physiological",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "normallyBenign": true,
      "riskInVulnerable": "moderate_to_high",
      "effects": [
        {
          "effect": "increased_heart_rate",
          "prevalence": {
            "over100bpm": 25,
            "unit": "percent",
            "dose": 200,
            "doseUnit": "mcg",
            "citation": "holze_2022"
          },
          "severity": "Usually benign"
        },
        {
          "effect": "increased_blood_pressure",
          "severity": "Moderate increases typical",
          "risk": "Problematic in pre-existing cardiovascular disease"
        },
        {
          "effect": "increased_body_temperature",
          "prevalence": {
            "over38C": 34,
            "unit": "percent",
            "dose": 200,
            "doseUnit": "mcg",
            "citation": "holze_2022"
          },
          "risk": "Hyperthermia possible with exertion/hot environment"
        }
      ],
      "vulnerablePopulations": [
        "Pre-existing heart conditions",
        "Hypertension",
        "Arrhythmias"
      ],
      "lifeThreateningRisk": "Low in healthy individuals; elevated in cardiovascular disease",
      "citations": ["holze_2022", "romeo_2024"]
    },
    {
      "id": "ae_lsd_somatic_001",
      "name": "Other Physical Symptoms",
      "category": "physiological",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "symptoms": [
        {
          "symptom": "sweating",
          "prevalence": 26.5,
          "unit": "percent",
          "context": "EMT seekers",
          "citation": "kopra_2022"
        },
        {
          "symptom": "palpitations",
          "prevalence": 25.5,
          "unit": "percent",
          "context": "EMT seekers",
          "citation": "kopra_2022"
        },
        {
          "symptom": "difficulty_breathing",
          "prevalence": 20.6,
          "unit": "percent",
          "context": "EMT seekers",
          "citation": "kopra_2022"
        },
        {
          "symptom": "nausea_vomiting",
          "prevalence": 17.6,
          "unit": "percent",
          "context": "EMT seekers",
          "citation": "kopra_2022"
        },
        {
          "symptom": "headache",
          "commonality": "reported",
          "citations": ["holze_2022", "kopra_2022"]
        },
        {
          "symptom": "mydriasis",
          "description": "Pupil dilation",
          "commonality": "very common"
        }
      ],
      "duration": "Typically subside after effects wear off",
      "management": "Supportive care; usually self-limiting"
    },
    {
      "id": "ae_lsd_overdose_001",
      "name": "Overdose",
      "category": "toxicological",
      "timeframe": "acute",
      "severity": "critical",
      "rarity": "rare",
      "caseReports": true,
      "effects": [
        "Coma",
        "Severe hyperthermia",
        "Bleeding complications",
        "Respiratory depression",
        "Cardiovascular collapse"
      ],
      "mortality": "Accidental deaths documented but very rare",
      "prevention": [
        "Accurate dosing",
        "Start low",
        "Avoid unknown sources",
        "Test substances"
      ],
      "citations": ["leonard_2018", "martins_2023"]
    },
    {
      "id": "ae_lsd_hppd_001",
      "name": "Hallucinogen Persisting Perception Disorder (HPPD)",
      "category": "perceptual",
      "timeframe": "long_term",
      "severity": "variable",
      "types": [
        {
          "type": "Type I",
          "description": "Transient, benign flashbacks",
          "distress": "minimal",
          "impairment": "none_to_minimal"
        },
        {
          "type": "Type II",
          "description": "Chronic, potentially distressing",
          "distress": "moderate_to_severe",
          "impairment": "variable"
        }
      ],
      "prevalence": [
        {
          "finding": "15% reported visual disturbances without further drug use",
          "citation": "halpern_2003"
        },
        {
          "finding": "10% reported long-term perceptual changes when asked directly",
          "significance": "73% did not consider changes significant",
          "citation": "carhart-harris_2010"
        },
        {
          "finding": "69% of former LSD users reported flashbacks",
          "coOccurrence": "66-79% also had long-term anxiety",
          "citation": "larsen_2016"
        },
        {
          "finding": "Range 15-77% across studies",
          "note": "Rates may be inflated due to methodological concerns",
          "citation": "ortiz_bernal_2022"
        }
      ],
      "visualSymptoms": [
        "Visual snow",
        "Flashes",
        "Floaters",
        "Afterimages",
        "Palinopsia",
        "Intensified colors",
        "Trailing",
        "Geometric patterns",
        "Halos"
      ],
      "dissociativeSymptoms": [
        "Depersonalization",
        "Derealization"
      ],
      "riskFactors": [
        "Frequent use",
        "High doses",
        "Long-term use",
        "Polydrug use (especially alcohol, cannabis)",
        "Young age",
        "History of substance misuse"
      ],
      "onsetPattern": "Can occur after single use but more common with chronic use",
      "clinicalTrials": {
        "contemporary": "No cases reported in contemporary clinical trials",
        "context": "Thought to be less common in controlled settings"
      },
      "subjectiveExperience": "Some experience as non-harmful or meaningful; others find distressing",
      "citations": ["halpern_2003", "carhart-harris_2010", "larsen_2016", "ortiz_bernal_2022", "lacroix_2024"]
    },
    {
      "id": "ae_lsd_flashbacks_001",
      "name": "Flashbacks",
      "category": "perceptual",
      "timeframe": "long_term",
      "severity": "variable",
      "description": "Spontaneous recurrence of aspects of LSD experience",
      "relationship": "Sometimes linked to HPPD but can occur independently",
      "prevalence": [
        {
          "range": {"min": 10, "max": 35},
          "unit": "percent",
          "note": "Not all distressing or harmful",
          "citation": "kopra_2022"
        },
        {
          "value": 69,
          "unit": "percent",
          "context": "Former LSD users",
          "citation": "larsen_2016"
        },
        {
          "value": 15,
          "unit": "percent",
          "context": "Uncontrolled LSD-like experiences without further drug use",
          "citation": "halpern_2003"
        }
      ],
      "triggers": [
        "Stress",
        "Fatigue",
        "Cannabis use",
        "Dark environments",
        "Sensory deprivation",
        "Exercise"
      ],
      "valence": "Range from benign to distressing",
      "duration": "Typically brief (seconds to minutes)",
      "citations": ["kopra_2022", "larsen_2016", "halpern_2003"]
    },
    {
      "id": "ae_lsd_prolonged_psychosis_001",
      "name": "Prolonged Psychotic Reactions",
      "category": "psychological",
      "timeframe": "long_term",
      "severity": "severe",
      "rarity": "rare",
      "duration": "Days, weeks, or longer",
      "prevalence": [
        {
          "value": 1.3,
          "unit": "percent",
          "context": "Persistent psychotic symptoms",
          "citation": "carhart-harris_2010"
        },
        {
          "value": 57,
          "unit": "percent",
          "context": "Of those with bad experiences developed extended psychosis",
          "citation": "rosenblat_nd"
        },
        {
          "historicalRate": {"min": 0.08, "max": 4.6},
          "unit": "percent",
          "context": "Range in studies; higher in psychiatric patients",
          "citation": "johnson_2008"
        }
      ],
      "symptoms": [
        "Paranoia",
        "Hallucinosis",
        "Derealization",
        "Disorganized thinking",
        "Delusions",
        "Loss of reality testing"
      ],
      "riskFactors": [
        "Personal history of psychosis",
        "Family history of psychosis",
        "Pre-existing psychiatric vulnerability",
        "Uncontrolled settings",
        "High doses"
      ],
      "context": "More common in uncontrolled settings and vulnerable individuals",
      "treatment": [
        "Psychiatric evaluation",
        "Antipsychotic medication",
        "Supportive therapy",
        "Hospitalization if severe"
      ],
      "citations": ["carhart-harris_2010", "rosenblat_nd", "johnson_2008"]
    },
    {
      "id": "ae_lsd_anxiety_depression_longterm_001",
      "name": "Persistent Anxiety and Depression",
      "category": "psychological",
      "timeframe": "long_term",
      "severity": "moderate",
      "prevalence": [
        {
          "anxiety": 1.9,
          "depression": 1.1,
          "unit": "percent",
          "citation": "carhart-harris_2010"
        },
        {
          "value": 87,
          "unit": "percent",
          "context": "Anxiety symptoms arose or worsened in those with negative psychological responses",
          "citation": "bremler_2023"
        }
      ],
      "description": "Worsening or new onset of anxiety or depression after LSD use",
      "riskFactors": [
        "Pre-existing anxiety or depression",
        "Bad trip experience",
        "Challenging experience",
        "Lack of integration support"
      ],
      "duration": "Variable; can persist for weeks to months",
      "treatment": [
        "Psychotherapy",
        "Integration support",
        "Medication if needed",
        "Support groups"
      ],
      "citations": ["carhart-harris_2010", "bremler_2023"]
    },
    {
      "id": "ae_lsd_personality_changes_001",
      "name": "Personality Changes",
      "category": "psychological",
      "timeframe": "long_term",
      "severity": "variable",
      "evidenceQuality": "weak",
      "historicalClaims": "Chronic LSD use associated with personality changes in older literature",
      "modernEvidence": "Not confirmed in recent studies",
      "temporaryShifts": "Some individuals may experience temporary shifts in sense of self or behavior",
      "permanentChanges": "No solid evidence for permanent alterations",
      "citations": ["halpern_1999", "barnett_2024"]
    },
    {
      "id": "ae_lsd_suicidality_longterm_001",
      "name": "Long-Term Suicidality",
      "category": "psychological",
      "timeframe": "long_term",
      "severity": "critical",
      "rarity": "rare",
      "prevalence": {
        "attempts": 1.2,
        "completed": 0.4,
        "unit": "per_1000_patients",
        "citation": "johnson_2008"
      },
      "causality": "Unclear; may relate to pre-existing issues",
      "context": "More common with underlying mental health conditions",
      "riskFactors": [
        "Pre-existing depression",
        "History of suicidal ideation",
        "Significant distress after experience",
        "Lack of support"
      ],
      "prevention": [
        "Thorough screening",
        "Integration support",
        "Mental health follow-up",
        "Crisis resources"
      ],
      "citation": "johnson_2008"
    },
    {
      "id": "ae_lsd_psychiatric_diagnosis_001",
      "name": "New Psychiatric Diagnoses Post-Use",
      "category": "psychological",
      "timeframe": "long_term",
      "severity": "variable",
      "prevalence": [
        {
          "value": 37.5,
          "unit": "percent",
          "context": "Diagnosed with psychiatric condition after psychedelic experience",
          "citation": "bremler_2023"
        },
        {
          "value": 14,
          "unit": "percent",
          "context": "Developed schizophrenia or delusional disorder 25 years after LSD treatment",
          "citation": "larsen_2016"
        },
        {
          "value": 25,
          "unit": "percent",
          "context": "Developed bipolar or depressive disorder 25 years after LSD treatment",
          "citation": "larsen_2016"
        }
      ],
      "note": "More common in individuals with pre-existing vulnerabilities",
      "causality": "Complex; may unmask latent conditions or exacerbate vulnerabilities",
      "conditions": [
        "Schizophrenia",
        "Delusional disorder",
        "Bipolar disorder",
        "Major depression",
        "Anxiety disorders"
      ],
      "citations": ["bremler_2023", "larsen_2016"]
    },
    {
      "id": "ae_lsd_cardiovascular_longterm_001",
      "name": "Long-Term Cardiovascular Effects",
      "category": "physiological",
      "timeframe": "long_term",
      "severity": "unclear",
      "evidenceQuality": "weak",
      "description": "Potential long-term cardiovascular effects not well understood",
      "concerns": [
        {
          "concern": "valvular_heart_disease",
          "mechanism": "LSD as 5-HT2B agonist",
          "context": "Particularly with long-term microdosing",
          "evidenceQuality": "theoretical_concern",
          "citation": "bornemann_2020"
        }
      ],
      "recommendation": "More research needed; caution with long-term regular use",
      "citation": "bornemann_2020"
    },
    {
      "id": "ae_lsd_neurotoxicity_001",
      "name": "Neurotoxicity",
      "category": "physiological",
      "timeframe": "long_term",
      "severity": "unclear",
      "evidenceQuality": "conflicting",
      "description": "Long-term effects on brain not well understood",
      "findings": [
        "Some studies suggest potential neurotoxic effects",
        "Others find no evidence of neurotoxicity",
        "Generally considered to have low neurotoxicity"
      ],
      "recommendation": "More research needed",
      "citation": "larsen_2016"
    }
  ],

  "lsdMicrodosingAdverseEvents": [
    {
      "id": "ae_micro_psychological_001",
      "name": "Microdosing Psychological Effects",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "prevalence": {
        "adverseEffects": 20,
        "noSideEffects": 30,
        "unit": "percent",
        "sampleSize": 1116,
        "citation": "wells_2024"
      },
      "symptoms": [
        {
          "symptom": "increased_anxiety",
          "prevalence": {"min": 81, "max": 93},
          "unit": "percent",
          "citation": "bremler_2023"
        },
        {
          "symptom": "emotional_discomfort",
          "citations": ["wells_2024", "hutten_2019"]
        },
        {
          "symptom": "racing_thoughts",
          "prevalence": 9.69,
          "unit": "percent",
          "citation": "petranker_2022"
        },
        {
          "symptom": "confusion",
          "prevalence": 9.69,
          "unit": "percent",
          "citation": "petranker_2022"
        },
        {
          "symptom": "memory_problems",
          "prevalence": 9.69,
          "unit": "percent",
          "citation": "petranker_2022"
        },
        {
          "symptom": "overstimulation",
          "citation": "lea_2020"
        },
        {
          "symptom": "difficulty_concentrating",
          "citation": "lea_2020"
        },
        {
          "symptom": "dissociation_rumination",
          "prevalence": 5.51,
          "unit": "percent",
          "citation": "petranker_2022"
        }
      ],
      "duration": "Usually transient; 1-3% report effects lasting days",
      "doseDependence": "More common at higher microdoses (15-20 mcg)"
    },
    {
      "id": "ae_micro_physiological_001",
      "name": "Microdosing Physiological Effects",
      "category": "physiological",
      "timeframe": "acute",
      "severity": "mild",
      "symptoms": [
        {
          "symptom": "headaches",
          "prevalence": 7.67,
          "unit": "percent",
          "citations": ["murphy_2024", "andersen_2021", "straumann_2024", "petranker_2022"]
        },
        {
          "symptom": "cold_sensations",
          "citation": "murphy_2024"
        },
        {
          "symptom": "feelings_of_abnormality",
          "citation": "murphy_2024"
        },
        {
          "symptom": "general_physiological_discomfort",
          "prevalence": 12,
          "unit": "percent",
          "dose": "low-dose conditions",
          "citation": "bornemann_2020"
        },
        {
          "symptom": "restlessness_fatigue",
          "prevalence": 10.59,
          "unit": "percent",
          "citation": "petranker_2022"
        },
        {
          "symptom": "stomach_pain",
          "prevalence": 7.67,
          "unit": "percent",
          "citation": "petranker_2022"
        },
        {
          "symptom": "sleep_problems",
          "prevalence": 7.67,
          "unit": "percent",
          "note": "Sleep quality generally not affected",
          "citations": ["petranker_2022", "polito_2024"]
        },
        {
          "symptom": "loss_of_appetite",
          "citation": "observed"
        }
      ],
      "cardiovascular": {
        "heartRate": "Mixed findings; some studies show no change, others note increases",
        "bloodPressure": "Variable effects",
        "citation": "polito_2024"
      },
      "balance": "No effects on balance reported"
    },
    {
      "id": "ae_micro_perceptual_001",
      "name": "Perceptual Effects at Microdose",
      "category": "perceptual",
      "timeframe": "acute",
      "severity": "mild",
      "description": "Some users report noticeable psychoactive effects even at microdoses",
      "prevalence": {
        "at10_20mcg": "Some users report effects",
        "at25mcg": "Clearer effects; sometimes called 'minidose'",
        "citations": ["murphy_2024", "holze_2021"]
      },
      "note": "Challenges definition of 'sub-perceptual'"
    },
    {
      "id": "ae_micro_longterm_001",
      "name": "Long-Term Microdosing Effects",
      "category": "mixed",
      "timeframe": "long_term",
      "severity": "variable",
      "rarity": "1-3% report negative effects beyond typical duration",
      "concernsUnstudied": true,
      "cardiovascular": {
        "concern": "5-HT2B receptor effects",
        "potentialRisk": "Valvular heart disease",
        "evidenceQuality": "theoretical",
        "recommendation": "More research needed",
        "citations": ["bornemann_2020", "savides_2024"]
      },
      "hppd": {
        "risk": "Possible but rare",
        "note": "More commonly associated with full doses"
      },
      "flashbacks": {
        "prevalence": "Rare (2% noted with mescaline; similar likely for LSD)",
        "citation": "aday_2020"
      }
    },
    {
      "id": "ae_micro_discontinuation_001",
      "name": "Reasons for Microdosing Discontinuation",
      "category": "behavioral",
      "mostCommon": "Perceived lack of efficacy",
      "negativeEffects": "Less common reason but occurs",
      "pattern": "Especially when psychological and physical effects occur together",
      "citation": "hutten_2019"
    },
    {
      "id": "ae_micro_dosing_challenges_001",
      "name": "Dosing Accuracy Challenges",
      "category": "practical",
      "severity": "moderate",
      "issues": [
        {
          "issue": "inconsistent_purity",
          "description": "Variable LSD content in illicit supplies",
          "risk": "Unpredictable dosing"
        },
        {
          "issue": "cutting_blotters",
          "description": "Uneven distribution when cutting tabs",
          "risk": "Hot spots or weak areas",
          "citation": "miller_2024"
        },
        {
          "issue": "contamination",
          "description": "Adulterants may be present",
          "risk": "Unexpected effects or toxicity"
        },
        {
          "issue": "finding_sweet_spot",
          "description": "Multiple attempts needed to find optimal dose",
          "citation": "lea_2020"
        }
      ],
      "solution": "Volumetric dosing recommended for consistency",
      "citation": "miller_2024"
    },
    {
      "id": "ae_micro_polydrug_001",
      "name": "Microdosing with Other Substances",
      "category": "interaction",
      "severity": "moderate",
      "concern": "Concurrent use alters effects",
      "substances": ["alcohol", "caffeine"],
      "impact": "Difficult to isolate LSD effects",
      "userBehavior": "Some avoid microdosing when physically unwell or using other substances",
      "citations": ["baxter_2024", "miller_2024"]
    },
    {
      "id": "ae_micro_expectation_001",
      "name": "Expectation Effects",
      "category": "methodological",
      "concern": "Expectation of effects can confound results",
      "context": "Particularly in studies using microdose as placebo",
      "implication": "Difficult to separate true drug effects from expectancy",
      "citation": "bornemann_2020"
    }
  ],

  "contaminationQualityIssues": [
    {
      "id": "contam_lsd_potency_001",
      "name": "Variable Potency in Blotter Paper",
      "category": "quality",
      "severity": "high",
      "description": "Uneven distribution of LSD across blotter paper",
      "mechanism": "LSD may not be evenly applied to paper",
      "consequences": [
        "Hot spots with higher concentrations",
        "Cold spots with little or no LSD",
        "Unpredictable dosing",
        "Accidental overdose",
        "Weak or no effects from some portions"
      ],
      "microdosing": "Particularly problematic for microdosing where precision needed",
      "prevention": [
        "Volumetric dosing",
        "Test doses",
        "Trusted sources"
      ],
      "citation": "miller_2024"
    },
    {
      "id": "contam_lsd_adulterants_001",
      "name": "Adulteration with NBOMes",
      "category": "contamination",
      "severity": "critical",
      "description": "NBOMe compounds sold as LSD",
      "commonAdulterants": [
        "25I-NBOMe",
        "25C-NBOMe",
        "25B-NBOMe"
      ],
      "risks": [
        "Higher toxicity than LSD",
        "Seizures",
        "Severe hallucinations",
        "Vasoconstriction",
        "Hyperthermia",
        "Deaths documented"
      ],
      "differentialDiagnosis": "NBOMes have bitter taste; LSD is tasteless",
      "prevention": [
        "Reagent testing with Ehrlich's reagent",
        "If tastes bitter, spit out",
        "Trusted sources"
      ],
      "citations": ["hirschfeld_2021", "malcolm_2022"]
    },
    {
      "id": "contam_lsd_dox_001",
      "name": "Adulteration with DOx Compounds",
      "category": "contamination",
      "severity": "high",
      "description": "Dimethoxyamphetamines (DOx family) sold as LSD",
      "examples": [
        "DOM",
        "DOI",
        "DOB"
      ],
      "risks": [
        "Severe side effects",
        "Much longer duration (24-36 hours)",
        "Higher toxicity",
        "Vasoconstriction",
        "Hospitalizations"
      ],
      "prevention": [
        "Substance testing",
        "Start with low dose",
        "Trusted sources"
      ]
    },
    {
      "id": "contam_lsd_atropine_001",
      "name": "Atropine-like Contamination",
      "category": "contamination",
      "severity": "high",
      "description": "Illicitly manufactured LSD contaminated with atropine-like substances",
      "risks": [
        "Anticholinergic toxicity",
        "Psychotic symptoms",
        "Hyperthermia",
        "Tachycardia",
        "Mydriasis",
        "Urinary retention",
        "Confusion"
      ],
      "citation": "sabe_2024"
    },
    {
      "id": "contam_lsd_misidentification_001",
      "name": "Misidentification in Drug Supply",
      "category": "sourcing",
      "severity": "high",
      "description": "LSD found in samples sold as other drugs",
      "example": "LSD found in cocaine samples",
      "risk": "Unexpected psychedelic effects",
      "implication": "Highlights unreliability of illicit drug market",
      "citations": ["hirschfeld_2021"]
    },
    {
      "id": "contam_lsd_serotonin_syndrome_risk_001",
      "name": "Contamination Increasing Serotonin Syndrome Risk",
      "category": "interaction",
      "severity": "critical",
      "description": "Contaminated LSD combined with serotonergic drugs",
      "mechanism": "Unknown adulterants may potentiate serotonin effects",
      "risk": "Serotonin toxicity when combined with SSRIs, MAOIs",
      "prevention": [
        "Test substances",
        "Know all medications being taken",
        "Avoid combinations"
      ],
      "citations": ["hirschfeld_2021", "malcolm_2022"]
    },
    {
      "id": "contam_lsd_unregulated_market_001",
      "name": "Lack of Quality Control in Illicit Market",
      "category": "regulatory",
      "severity": "high",
      "description": "No regulatory oversight of illicit LSD",
      "consequences": [
        "Cannot verify purity",
        "Cannot verify potency",
        "Cannot verify identity",
        "Exposure to unknown adulterants",
        "Unpredictable effects"
      ],
      "compoundingFactors": [
        "Unregulated synthesis",
        "Unknown intermediates",
        "Storage degradation",
        "Intentional adulteration"
      ],
      "citations": ["bremler_2023", "glynos_2023"]
    }
  ],

  "harmReductionStrategies": [
    {
      "id": "hr_lsd_substance_testing_001",
      "name": "Substance Testing",
      "category": "pre_use",
      "importance": "critical",
      "methods": [
        {
          "method": "reagent_testing",
          "reagent": "Ehrlich's reagent",
          "detects": "Presence of indoles (LSD, psilocybin)",
          "limitations": [
            "Cannot detect all adulterants",
            "Cannot measure quantity",
            "Cannot predict individual response"
          ],
          "availability": "Affordable, accessible",
          "citations": ["miller_2024", "lea_2020"]
        },
        {
          "method": "drug_checking_services",
          "description": "Professional laboratory analysis",
          "availability": "Variable by location",
          "advantage": "More comprehensive analysis"
        },
        {
          "method": "test_dose",
          "description": "Taking small amount to assess purity/potency",
          "prevalence": "31.3% of first-time users took test dose",
          "recommendation": "Strongly recommended",
          "citation": "baxter_2024"
        }
      ],
      "bitterTaste": "If blotter tastes bitter, it's likely not LSD - spit it out"
    },
    {
      "id": "hr_lsd_start_low_001",
      "name": "Start Low, Go Slow",
      "category": "dosing",
      "importance": "high",
      "description": "Begin with low doses, especially for first-time users",
      "rationale": [
        "Gauge individual sensitivity",
        "Minimize risk of overwhelming experience",
        "Reduce likelihood of adverse effects"
      ],
      "recommendations": [
        "First-time: 50-75 mcg",
        "Wait for full effects before considering more",
        "Gradual dose increase if continuing use"
      ],
      "citations": ["bornemann_2020", "baxter_2024", "basedow_2024"]
    },
    {
      "id": "hr_lsd_set_setting_001",
      "name": "Optimize Set and Setting",
      "category": "environmental",
      "importance": "critical",
      "set_components": [
        "Positive mindset",
        "Clear intentions",
        "Emotional stability",
        "Adequate preparation",
        "Realistic expectations"
      ],
      "setting_components": [
        "Safe, comfortable environment",
        "Familiar location preferred",
        "Minimize distractions",
        "Temperature control",
        "Access to bathroom",
        "Comfortable seating/lying area",
        "Supportive people present"
      ],
      "firstTimeUsers": "79.6% took LSD with close friend, group of friends, or partner",
      "citations": ["baxter_2024", "bremler_2023", "kopra_2022"]
    },
    {
      "id": "hr_lsd_trip_sitter_001",
      "name": "Trip Sitter/Trusted Support Person",
      "category": "social",
      "importance": "high",
      "description": "Experienced, sober person present during experience",
      "roles": [
        "Provide reassurance",
        "Ensure physical safety",
        "Help with basic needs",
        "Assist with challenging moments",
        "Be calm presence"
      ],
      "characteristics": [
        "Trustworthy",
        "Calm demeanor",
        "Knowledge of psychedelics",
        "Non-judgmental",
        "Available throughout experience"
      ],
      "prevalence": "Common practice among experienced users",
      "citations": ["baxter_2024", "edwards_2023", "palmer_2022"]
    },
    {
      "id": "hr_lsd_avoid_mixing_001",
      "name": "Avoid Polydrug Use",
      "category": "safety",
      "importance": "critical",
      "description": "Do not combine LSD with other substances",
      "specificWarnings": [
        {
          "substance": "alcohol",
          "risk": "Increased adverse effects, impaired judgment"
        },
        {
          "substance": "SSRIs",
          "risk": "Serotonin syndrome"
        },
        {
          "substance": "MAOIs",
          "risk": "Severe serotonin syndrome, potentially fatal"
        },
        {
          "substance": "lithium",
          "risk": "Dangerous interaction, seizures"
        },
        {
          "substance": "cannabis",
          "risk": "Unpredictable intensification, increased anxiety"
        }
      ],
      "generalRule": "Use LSD alone, not in combination",
      "deathData": "82% of psychedelic-related deaths involved polydrug use",
      "citation": "kopra_2025"
    },
    {
      "id": "hr_lsd_medication_review_001",
      "name": "Medication Review",
      "category": "medical",
      "importance": "critical",
      "description": "Review all medications before LSD use",
      "procedure": [
        "List all prescription medications",
        "Include over-the-counter drugs",
        "Note supplements and herbs",
        "Consult with knowledgeable professional",
        "Stop contraindicated medications under supervision"
      ],
      "absoluteContraindications": [
        "MAOIs",
        "Lithium"
      ],
      "relativeContraindications": [
        "SSRIs",
        "Antipsychotics",
        "Benzodiazepines (may reduce effects)"
      ],
      "citation": "davis_nd"
    },
    {
      "id": "hr_lsd_preparation_001",
      "name": "Comprehensive Preparation",
      "category": "pre_use",
      "importance": "high",
      "components": [
        "Psychoeducation about effects",
        "Setting clear intentions",
        "Life review with facilitator",
        "Addressing fears and concerns",
        "Learning coping strategies",
        "Understanding set and setting",
        "Informed consent process"
      ],
      "duration": "Multiple sessions recommended",
      "effectiveness": "Associated with better outcomes",
      "citation": "garcia-romeu_2018"
    },
    {
      "id": "hr_lsd_integration_001",
      "name": "Integration Support",
      "category": "post_use",
      "importance": "high",
      "description": "Processing and making meaning of experience",
      "timing": "Begin 1-2 days post-session, continue for weeks to months",
      "modalities": [
        "Individual therapy",
        "Group integration circles",
        "Journaling",
        "Creative expression",
        "Contemplative practices",
        "Peer support"
      ],
      "benefits": [
        "Make sense of experience",
        "Translate insights to behavior change",
        "Process challenging material",
        "Prevent maladaptive beliefs",
        "Reduce extended difficulties"
      ],
      "citations": ["garcia-romeu_2018", "robinson_2024", "evans_2023"]
    },
    {
      "id": "hr_lsd_volumetric_dosing_001",
      "name": "Volumetric Dosing for Microdosing",
      "category": "dosing",
      "importance": "high",
      "context": "Especially important for microdosing",
      "method": "Dissolve known quantity of LSD in measured volume of liquid",
      "advantages": [
        "Consistent dosing",
        "Avoid hot spots in blotters",
        "Precise measurement",
        "Easy dose adjustment"
      ],
      "procedure": [
        "Use distilled water or alcohol",
        "Calculate concentration",
        "Store in dark, cool place",
        "Measure doses volumetrically"
      ],
      "citation": "miller_2024"
    },
    {
      "id": "hr_lsd_trusted_sources_001",
      "name": "Trusted Sources",
      "category": "sourcing",
      "importance": "high",
      "description": "Obtain substances from reliable sources",
      "considerations": [
        "Reputation",
        "Consistency",
        "Willingness to have substances tested",
        "Transparency about sourcing"
      ],
      "limitation": "Still no guarantee in unregulated market",
      "citations": ["lancelotta_2020", "palmer_2022", "miller_2024"]
    },
    {
      "id": "hr_lsd_helplines_001",
      "name": "Access to Crisis Support",
      "category": "emergency",
      "importance": "high",
      "services": [
        {
          "service": "Fireside Project",
          "type": "Telephone helpline",
          "availability": "24/7",
          "effectiveness": "65.9% de-escalation rate"
        },
        {
          "service": "Zendo Project",
          "type": "On-site support at events",
          "model": "Peer support"
        }
      ],
      "prevention": "Can prevent need for emergency services",
      "citations": ["pleet_2023", "canady_2023", "ruane_2015"]
    },
    {
      "id": "hr_lsd_education_001",
      "name": "Evidence-Based Education",
      "category": "prevention",
      "importance": "high",
      "content": [
        "Accurate risk information",
        "Benefits and limitations",
        "Harm reduction practices",
        "How to recognize adverse reactions",
        "When to seek help"
      ],
      "delivery": [
        "Peer networks",
        "Online resources",
        "Educational workshops",
        "Healthcare provider education"
      ],
      "targetPopulations": [
        "Potential users",
        "Current users",
        "Healthcare providers",
        "First responders"
      ],
      "citations": ["kopra_2025", "edwards_2023"]
    }
  ],

  "clinicalConsiderations": [
    {
      "id": "clinical_screening_001",
      "name": "Comprehensive Screening Protocol",
      "importance": "critical",
      "components": [
        {
          "area": "psychiatric_history",
          "assess": [
            "Personal history of psychosis, bipolar, severe depression",
            "Family history of psychotic disorders, bipolar",
            "Current symptoms",
            "Previous adverse reactions to drugs",
            "Personality disorders",
            "PTSD and trauma history"
          ]
        },
        {
          "area": "medical_history",
          "assess": [
            "Cardiovascular conditions",
            "Neurological conditions",
            "Seizure history",
            "Liver and kidney function",
            "Pregnancy status"
          ]
        },
        {
          "area": "medication_review",
          "assess": [
            "All prescription medications",
            "Over-the-counter drugs",
            "Supplements",
            "Dangerous interactions"
          ]
        },
        {
          "area": "substance_use",
          "assess": [
            "Current use of alcohol, cannabis, other drugs",
            "History of substance use disorder",
            "Polydrug patterns"
          ]
        }
      ],
      "tools": [
        "Structured clinical interviews",
        "Validated questionnaires",
        "Medical examination",
        "ECG if cardiovascular concerns"
      ],
      "citations": ["garcia-romeu_2018", "rosenblat_2023", "aday_2020"]
    },
    {
      "id": "clinical_monitoring_001",
      "name": "Session Monitoring",
      "importance": "critical",
      "vitals": [
        {
          "parameter": "heart_rate",
          "frequency": "Regular intervals",
          "concern": ">100 bpm in 25% at 200 mcg"
        },
        {
          "parameter": "blood_pressure",
          "frequency": "Regular intervals",
          "concern": "Moderate increases expected"
        },
        {
          "parameter": "body_temperature",
          "frequency": "Regular intervals",
          "concern": ">38°C in 34% at 200 mcg"
        }
      ],
      "psychological": [
        "Continuous observation",
        "Regular verbal contact",
        "Assessment of anxiety/distress",
        "Suicidal ideation monitoring"
      ],
      "documentation": "All observations and interventions",
      "citations": ["holze_2022", "carbonaro_2016"]
    },
    {
      "id": "clinical_informed_consent_001",
      "name": "Enhanced Informed Consent",
      "importance": "critical",
      "description": "Comprehensive consent process specific to psychedelics",
      "components": [
        "Detailed description of effects",
        "Psychological risks",
        "Physical risks",
        "Possibility of challenging experiences",
        "Trauma reactivation risk",
        "Long-term effect uncertainties",
        "Alternatives to treatment",
        "Right to withdraw"
      ],
      "enhanced": "Goes beyond typical psychiatric consent",
      "discussion": [
        "Potential for shifts in values/personality",
        "Changes in judgment and beliefs",
        "Increased suggestibility during experience",
        "Power dynamics in therapeutic relationship"
      ],
      "citation": "rajwani_2022"
    },
    {
      "id": "clinical_therapist_training_001",
      "name": "Therapist Training and Competencies",
      "importance": "critical",
      "coreCompetencies": [
        "Understanding psychedelic pharmacology",
        "Crisis management skills",
        "Trauma-informed care",
        "Cultural competence",
        "Ethical boundaries",
        "Integration techniques",
        "Managing transference/countertransference"
      ],
      "training": [
        "Hyper-suggestibility awareness",
        "Enhanced transference and projection",
        "Ego-inflation risks",
        "Undue influence prevention",
        "Power dynamics"
      ],
      "supervision": "Ongoing supervision essential",
      "citations": ["wilson-poe_2024", "kruger_2024"]
    },
    {
      "id": "clinical_adverse_event_reporting_001",
      "name": "Systematic Adverse Event Assessment",
      "importance": "high",
      "challenge": "Underreporting in psychedelic research",
      "recommendations": [
        "Standardized assessment tools (e.g., SPSI)",
        "Specific targeted questions",
        "Open-ended questions",
        "Clinician-reported outcomes",
        "Patient-reported outcomes",
        "Reports from close others",
        "Multiple time points"
      ],
      "timing": [
        "During session",
        "Immediately post-session",
        "Days to weeks follow-up",
        "Long-term follow-up"
      ],
      "citations": ["palitsky_nd", "cheung_2024", "freitas_2024"]
    }
  ],

  "emergencyProtocols": [
    {
      "id": "emergency_lsd_nonpharm_001",
      "name": "Non-Pharmacological Crisis Management",
      "priority": "first_line",
      "interventions": [
        {
          "intervention": "reassurance",
          "description": "Remind experience is temporary, drug-related, safe",
          "tone": "Calm, empathetic",
          "effectiveness": "Sufficient for most cases"
        },
        {
          "intervention": "environmental_modification",
          "actions": [
            "Move to quiet area",
            "Reduce stimulation",
            "Dim lights",
            "Comfortable temperature"
          ]
        },
        {
          "intervention": "breathing_guidance",
          "technique": "Slow, deep breathing instructions"
        },
        {
          "intervention": "grounding",
          "techniques": [
            "Focus on physical sensations",
            "Present moment awareness",
            "Sensory focus"
          ]
        },
        {
          "intervention": "supportive_presence",
          "description": "Calm, non-judgmental presence",
          "avoid": "Arguing with altered perceptions"
        }
      ],
      "effectiveness": "High - manages most distress",
      "citations": ["garcia-romeu_2018", "johnson_2008"]
    },
    {
      "id": "emergency_lsd_pharm_001",
      "name": "Pharmacological Interventions",
      "priority": "second_line",
      "indication": "Non-pharmacological approaches insufficient",
      "medications": [
        {
          "drug": "diazepam",
          "status": "First-line pharmacological",
          "typical_dose": 10,
          "unit": "mg",
          "route": "oral",
          "emergency_dose": {"min": 15, "max": 30, "unit": "mg"},
          "mechanism": "Anxiolytic",
          "advantages": ["Rapid onset", "Shorter duration"],
          "availability": "Should be readily available"
        },
        {
          "drug": "antipsychotics",
          "examples": ["risperidone", "olanzapine"],
          "status": "Last resort",
          "indication": "Severe psychosis unresponsive to benzodiazepines",
          "avoid": "haloperidol (may worsen psychosis-like symptoms)",
          "cautions": "May cause unpleasant effects"
        }
      ],
      "citations": ["johnson_2008", "barnett_2021"]
    },
    {
      "id": "emergency_lsd_ems_001",
      "name": "Emergency Medical Services",
      "indication": [
        "Condition not improving",
        "Severe physiological symptoms",
        "Suicidal ideation/behavior",
        "Violent behavior",
        "Suspected overdose",
        "Medical emergency"
      ],
      "preparation": [
        "Emergency contact protocol",
        "Medical history available",
        "List of consumed substances"
      ],
      "prevalence": {
        "firstTimeUsers": 0.5,
        "generalUsers2020": 1,
        "unit": "percent"
      }
    }
  ],

  "researchGaps": [
    {
      "gap": "Long-term safety data",
      "description": "Limited long-term follow-up studies",
      "priority": "high"
    },
    {
      "gap": "Diversity in research",
      "description": "82.3% of participants 1993-2017 were non-Hispanic White",
      "impact": "Limited generalizability",
      "priority": "critical"
    },
    {
      "gap": "Cardiovascular effects of microdosing",
      "description": "5-HT2B agonism concerns understudied",
      "priority": "high"
    },
    {
      "gap": "Optimal dosing strategies",
      "description": "Individual dose optimization not well understood",
      "priority": "moderate"
    },
    {
      "gap": "Integration best practices",
      "description": "Limited evidence on optimal integration approaches",
      "priority": "moderate"
    },
    {
      "gap": "Neurotoxicity",
      "description": "Conflicting evidence on long-term brain effects",
      "priority": "high"
    },
    {
      "gap": "Mechanisms of therapeutic effects",
      "description": "How LSD produces therapeutic benefits unclear",
      "priority": "moderate"
    }
  ],

  "metadata": {
    "substanceId": "lsd_001",
    "documentSource": "LSD - Literature Review",
    "extractionDate": "2025-01-09",
    "totalCitations": "400+",
    "dateRange": "1960s-2024",
    "geographicScope": "Global, emphasis on North America and Europe",
    "evidenceQuality": "Variable by topic; strongest for acute effects, weaker for long-term outcomes",
    "knownLimitations": [
      "Underreporting of adverse events likely",
      "Limited diversity in research populations",
      "Few long-term follow-up studies",
      "Historical data quality variable",
      "Illicit use data less reliable than clinical",
      "Publication bias toward positive findings"
    ],
    "clinicalTrialsData": "Multiple clinical trials but smaller scale than other psychedelics",
    "naturalisticData": "Substantial observational and survey data"
  }
}